Cambridge’s TRIMTECH Therapeutics Brings Seed Round to €41 Million for Neurodegenerative Disease Work

TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million).

TRIMTECH Therapeutics Brings Total Seed Round to $47M with ...

TRIMTECH extends seed round to $47M for protein degradation drugs - European Biotechnology Magazine

UK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million. The post TRIMTECH extends seed round to $47M for protein degradation drugs appeared first on European Biotechnology Magazine.

Cambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease work

TRIMTECH Therapeutics, a Cambridge-based BioTech company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, has raised an additional €12 million ($14 million) in Seed funding to progress its proprietary platforms and differentiated portfolio. The financing was led by Johnson & Johnson’s corporate venture capital organisation, Johnson & Johnson Innovation – JJDC, Inc., …

New funding takes Trimtech Therapeutics’ seed round to £35.6m

Biotech firm Trimtech Therapeutics has raised an additional $14m (£10.6m) in seed funding, bringing the total for the round to $47m (£35.6m).  Trimtech Therapeutics is creating novel, highly selective, small molecule targeted protein degraders to combat neurodegenerative and inflammatory diseases.  With over 55 million people affected by Alzheimer’s disease and millions more diagnosed with other neurodegenerative disorders, the startup says its …

TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio

Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), and BGF